secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001558370-25-002708
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte Q4 core revenue +20%, total rev -45% on milestone comp; FY2025 core growth 8-15%
--------------------------------------------------------------------------------

- Q4 2024 total revenue $8.7M (-45% YoY); core revenue ex-milestones $8.6M (+20%); net loss $10.6M vs $5.3M.
- FY2024 total revenue $38.6M (-6%); core revenue $32.5M (+9%); gross margin 82%; net loss $41.1M vs $37.9M.
- Ended 2024 with $190.3M cash; 28 active SPLs (up from 23), 18 clinical SPL programs, 1 commercial.
- 2025 guidance: core revenue growth 8-15% (incl SeQure Dx); SPL rev ~$5M; cash target $160M year-end.
- Signed record six SPLs in 2024; added TG Therapeutics early 2025; SeQure Dx acquisition integrated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837025002708/0001558370-25-002708-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837025002708/mxct-20250311x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-002708

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer